文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

非戈替尼对比安慰剂对改善病情抗风湿药难治性中重度类风湿关节炎患者临床应答的影响:FINCH 2随机临床试验

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项为期24周的国际多中心3期随机对照试验纳入449例对至少1种生物制剂改善病情抗风湿药(bDMARD)应答不足或不耐受的活动性类风湿关节炎成人患者,比较非戈替尼200 mg、100 mg与安慰剂每日一次的效果。第12周非戈替尼200 mg组(66.0%)和100 mg组(57.5%)达到ACR20的比例均显著高于安慰剂组(31.1%),但作者指出仍需进一步研究评估长期疗效与安全性。

要点

  • 第12周ACR20应答率:非戈替尼200 mg组66.0%、100 mg组57.5%,均高于安慰剂组31.1%(两组P<.001)。
  • 在既往使用≥3种bDMARD的患者中,ACR20应答率分别为70.3%、58.8%和17.6%。
  • 非戈替尼组报告4例无并发症带状疱疹和1例视网膜静脉阻塞,无机会性感染、活动性结核、恶性肿瘤、胃肠道穿孔或死亡。

核心结论

  • 在对1种或以上bDMARD应答不足或不耐受的活动性类风湿关节炎患者中,非戈替尼100 mg每日一次或200 mg每日一次较安慰剂使第12周达到临床应答的患者比例显著更高,但需进一步研究评估长期疗效与安全性。

研究设计与样本

  • 24周、随机、安慰剂对照、国际多中心3期试验,于2016年7月至2018年6月在114个国际研究中心开展,随机分配449例成人患者(治疗448例),患者为中度至重度活动性类风湿关节炎且对1种或以上既往bDMARD应答不足或不耐受。
  • 干预为每日一次口服非戈替尼200 mg(n=148)、非戈替尼100 mg(n=153)或安慰剂(n=148),患者继续联用稳定的传统合成改善病情抗风湿药(csDMARDs)。
  • 主要终点为第12周达到美国风湿病学会20%改善标准(ACR20)的患者比例。

主要发现

  • 第12周ACR20应答率:非戈替尼200 mg组66.0%、非戈替尼100 mg组57.5%、安慰剂组31.1%;与安慰剂差值分别为34.9%(95%CI 23.5%-46.3%)和26.4%(95%CI 15.0%-37.9%),均P<.001。
  • 在既往使用≥3种bDMARD的患者中,第12周ACR20应答率分别为非戈替尼200 mg组70.3%、非戈替尼100 mg组58.8%、安慰剂组17.6%;与安慰剂差值分别为52.6%(95%CI 30.3%-75.0%)和41.2%(95%CI 17.3%-65.0%),均P<.001。
  • 最常见不良事件:非戈替尼200 mg组为鼻咽炎(10.2%);非戈替尼100 mg组为头痛、鼻咽炎和上呼吸道感染(各5.9%);安慰剂组为类风湿关节炎(6.1%)。
  • 非戈替尼组报告4例无并发症带状疱疹和1例视网膜静脉阻塞;未报告机会性感染、活动性结核、恶性肿瘤、胃肠道穿孔或死亡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者指出需进一步研究评估长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with active rheumatoid arthritis (RA) despite treatment with biologic disease-modifying antirheumatic drug (bDMARD) therapy need treatment options. OBJECTIVE: To evaluate the effects of filgotinib vs placebo on the signs and symptoms of RA in a treatment-refractory population. DESIGN, SETTING, AND PARTICIPANTS: A 24-week, randomized, placebo-controlled, multinational phase 3 trial conducted from July 2016 to June 2018 at 114 sites internationally, randomizing 449 adult patients (and treating 448) with moderately to severely active RA and inadequate response/intolerance to 1 or more prior bDMARDs. INTERVENTIONS: Filgotinib, 200 mg (n = 148); filgotinib, 100 mg (n = 153); or placebo (n = 148) once daily; patients continued concomitant stable conventional synthetic DMARDs (csDMARDs). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients who achieved 20% improvement in the American College of Rheumatology criteria (ACR20) at week 12. Secondary outcomes included week 12 assessments of low disease activity (disease activity score in 28 joints-C-reactive protein [DAS28-CRP] ≤3.2) and change in Health Assessment Questionnaire-Disability Index, 36-Item Short-Form Health Survey Physical Component, and Functional Assessment of Chronic Illness Therapy-Fatigue scores, as well as week 24 assessment of remission (DAS28-CRP <2.6) and adverse events. RESULTS: Among 448 patients who were treated (mean [SD] age, 56 [12] years; 360 women [80.4%]; mean [SD] DAS28-CRP score, 5.9 [0.96]; 105 [23.4%] with ≥3 prior bDMARDs), 381 (85%) completed the study. At week 12, more patients receiving filgotinib, 200 mg (66.0%) or 100 mg (57.5%), achieved ACR20 response (placebo, 31.1%; difference vs placebo: 34.9% [95% CI, 23.5%-46.3%] and 26.4% [95% CI, 15.0%-37.9%], respectively; both P < .001), including among patients with prior exposure to 3 or more bDMARDs (70.3%, 58.8%, and 17.6%, respectively; difference vs placebo: 52.6% [95% CI, 30.3%-75.0%] for filgotinib, 200 mg, and 41.2% [95% CI, 17.3%-65.0%] for filgotinib, 100 mg; both P < .001). The most common adverse events were nasopharyngitis (10.2%) for filgotinib, 200 mg; headache, nasopharyngitis, and upper respiratory infection (5.9% each) for filgotinib, 100 mg; and RA (6.1%) for placebo. Four uncomplicated herpes zoster cases and 1 retinal vein occlusion were reported with filgotinib; there were no opportunistic infections, active tuberculosis, malignancies, gastrointestinal perforations, or deaths. CONCLUSIONS AND RELEVANCE: Among patients with active RA who had an inadequate response or intolerance to 1 or more bDMARDs, filgotinib, 100 mg daily or 200 mg daily, compared with placebo resulted in a significantly greater proportion achieving a clinical response at week 12. However, further research is needed to assess longer-term efficacy and safety. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02873936.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019. PMID: 31334793. doi:10.1001/jama.2019.9055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。